newsfilter
← Latest News
GlobeNewswire·

X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

XFOR
  • X4 Pharmaceuticals will host a virtual Investor Day on Thursday, October 29, 2026, from 10:00 a.m. to 12:00 p.m. ET.
  • The event will feature discussions with management & key opinion leaders regarding mavorixafor as a potential treatment for chronic neutropenia.
  • Management will review the current status of the Phase 3 4WARD clinical trial & outline a planned Phase 2 trial combining mavorixafor with G-CSF to assess dose titration while maintaining normal neutrophil counts.
  • The Company will present the potential commercial opportunity for mavorixafor in chronic neutropenia.
  • Dr. Adam Craig, Executive Chairman, will host a fireside chat with Dr. Shreyans Gandhi of King's College Hospital & Dr. Julia Warren of Children's Hospital of Philadelphia, followed by a Q&A session.
  • Registration for the webcast is available on the X4 Pharmaceuticals website, with an archived replay to follow.
  • Dr. Gandhi specializes in bone marrow failure disorders, PNH, & has authored over 100 peer-reviewed articles.
  • Dr. Warren focuses on mitochondrial function in granulocyte fate decisions & pre-malignant clonal evolution in congenital neutropenia.
  • Mavorixafor is currently approved in the U.S. & EU as XOLREMDI for WHIM syndrome & holds Fast Track designation from the FDA for chronic neutropenia.
  • X4 Pharmaceuticals is headquartered in Boston, Massachusetts, & focuses on developing innovative therapies for rare hematology diseases.